Cristina Gasparetto1, Sundar Jagannath2, Robert M Rifkin3, Brian G M Durie4, Mohit Narang5, Howard R Terebelo6, Kathleen Toomey7, James W Hardin8, Lynne Wagner9, Sikander Ailawadhi10, James L Omel11, Shankar Srinivasan12, Mazaher Dhalla12, Donna Catamero12, Amani Kitali12, Amit Agarwal12, Rafat Abonour13. 1. Division of Hematologic Malignancies and Cellular Therapy, Duke University Medical Center, Durham, NC. Electronic address: gaspa001@mc.duke.edu. 2. Department of Hematology and Medical Oncology, Mount Sinai Hospital, New York, NY. 3. Department of Medical Oncology/Hematology, Rocky Mountain Cancer Centers US Oncology Research Denver, CO. 4. Department of Hematology/Oncology, Cedars-Sinai Medical Center, Los Angeles, CA. 5. Department of Medical Oncology/Hematology, Maryland Oncology Hematology, US Oncology Research Columbia, MD. 6. Department of Hematology, Internal Medicine, and Medical Oncology, Providence Cancer Institute, Southfield, MI. 7. Department of Internal Medicine, Medical Oncology, and Hematology, Steeplechase Cancer Center, Somerville, NJ. 8. Department of Epidemiology and Biostatistics, University of South Carolina, Columbia, SC. 9. Department of Social Sciences and Health Policy, Wake Forest School of Medicine, NC. 10. Department of Hematology/Oncology, Mayo Clinic, Jacksonville, FL. 11. Myeloma Research Advocate/Advisor, Grand Island, NE. 12. Bristol Myers Squibb, Princeton, NJ. 13. Department of Hematology/Oncology, Indiana University, Indianapolis, IN.
Abstract
BACKGROUND: The t (11;14) (q13;32) translocation [t (11;14)] is present in ∼20% of patients with newly diagnosed multiple myeloma (NDMM), but studies examining its prognostic ability have yielded divergent results, and data are lacking on outcomes from first-line therapy. PATIENTS AND METHODS: Data from the Connect MM Registry, a large US, multicenter, prospective observational cohort study of patients with NDMM were used to examine the effect of t (11;14) status on first-line therapy outcomes in the Overall population (n = 1574) and race groups (African American [AA] vs. non-African American [NAA]). RESULTS: Baseline characteristics were generally similar between patients with (n = 378) and without (n = 1196) t (11;14). Prevalence of t (11;14) was similar by race (AA, 27%; NAA, 24%). In the overall population, regardless of first-line therapy, t (11;14) status did not affect progression-free survival (hazard ratio, 1.02; P = 0.7675) or overall survival (hazard ratio, 0.99; P = .9417). AA patients with t (11;14) had higher likelihood of death (Nominal Cox regression P = .0298) vs. patients without t (11;14). CONCLUSIONS: Acknowledging observational study and inferential limitations, this exploratory analysis of a predominantly community-based population suggests that t (11;14) is a neutral prognostic factor in the general MM population but may be a negative factor for overall survival in AA patients.
BACKGROUND: The t (11;14) (q13;32) translocation [t (11;14)] is present in ∼20% of patients with newly diagnosed multiple myeloma (NDMM), but studies examining its prognostic ability have yielded divergent results, and data are lacking on outcomes from first-line therapy. PATIENTS AND METHODS: Data from the Connect MM Registry, a large US, multicenter, prospective observational cohort study of patients with NDMM were used to examine the effect of t (11;14) status on first-line therapy outcomes in the Overall population (n = 1574) and race groups (African American [AA] vs. non-African American [NAA]). RESULTS: Baseline characteristics were generally similar between patients with (n = 378) and without (n = 1196) t (11;14). Prevalence of t (11;14) was similar by race (AA, 27%; NAA, 24%). In the overall population, regardless of first-line therapy, t (11;14) status did not affect progression-free survival (hazard ratio, 1.02; P = 0.7675) or overall survival (hazard ratio, 0.99; P = .9417). AA patients with t (11;14) had higher likelihood of death (Nominal Cox regression P = .0298) vs. patients without t (11;14). CONCLUSIONS: Acknowledging observational study and inferential limitations, this exploratory analysis of a predominantly community-based population suggests that t (11;14) is a neutral prognostic factor in the general MM population but may be a negative factor for overall survival in AA patients.
Authors: Susan Bal; Shaji K Kumar; Rafael Fonseca; Francesca Gay; Vania Tm Hungria; Ahmet Dogan; Luciano J Costa Journal: Am J Cancer Res Date: 2022-07-15 Impact factor: 5.942